ID

35257

Description

Study ID: 102970 Clinical Study ID: 102970 Study Title: A 52-week Efficacy and Safety Study to Compare the Effect of Three Dosage Strengths of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on the Annual Rate of Exacerbations in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT01017952 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 3 Study Recruitment Status: Completed Generic Name: GW642444 Inhalation Powder; FF/GW642444 Inhalation Powder Trade Name: Fluticasone Furoate;Fluticasone Propionate;Fluticasone Propionate/Salmeterol;Salmeterol;Vilanterol Study Indication: Pulmonary Disease, Chronic Obstructive

Keywords

Versions (1)
  1. 2/25/19 2/25/19 -
Copyright Holder

GlaxoSmithKline

Uploaded on

February 25, 2019

DOI

To request one please log in.

License

Creative Commons BY-NC 3.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Effect of Fluticasone Furoate/GW642444 Inhalation Powder With GW642444 on Annual Rate of Exacerbations in Subjects with COPD; 102970

English

End of Study

1 forms  
  1. StudyEvent: ODM
    1. End of Study
Administrative Data
Description

Administrative Data

Site
Description

Study Site

Data type

text

Alias
UMLS CUI [1]
C2825164
Subject
Description

Clinical trial participant

Data type

text

Alias
UMLS CUI [1]
C1997894
Subject No.
Description

Clinical Trial Subject Unique Identifier

Data type

integer

Alias
UMLS CUI [1]
C2348585
Status of Treatment Blind
Description

Status of Treatment Blind

Alias
UMLS CUI-1
C2347038
UMLS CUI-2
C0449438
Was the treatment blind broken during the study?
Description

If yes, complete Non-Serious Adverse Events, Serious Adverse Event and/or Investigational Product forms as appropriate

Data type

boolean

Alias
UMLS CUI [1]
C3897431
Date blind broken
Description

Subject Unblinding Event Record, Date in time

Data type

date

Alias
UMLS CUI [1,1]
C3897431
UMLS CUI [1,2]
C0011008
Reason blind broken
Description

Subject Unblinding Event Record, Indication

Data type

text

Alias
UMLS CUI [1,1]
C3897431
UMLS CUI [1,2]
C0392360
Follow-Up Contact
Description

Follow-Up Contact

Alias
UMLS CUI-1
C1522577
Subject contacted for follow-up?
Description

Follow-up, Contact with, Study subject

Data type

boolean

Alias
UMLS CUI [1,1]
C1522577
UMLS CUI [1,2]
C0332158
UMLS CUI [1,3]
C0681850
Date of Visit/Assessment
Description

Date of Visit/Assessment

Alias
UMLS CUI-1
C1320303
UMLS CUI-2
C2985720
Date of visit/assessment
Description

Date of visit, Assessment Date

Data type

date

Alias
UMLS CUI [1,1]
C1320303
UMLS CUI [1,2]
C2985720
Study Conclusion
Description

Study Conclusion

Alias
UMLS CUI-1
C0008976
UMLS CUI-2
C1707478
Date of subject completion or withdrawal
Description

Study End Date, Patient withdrawn from trial, Date in time

Data type

date

Alias
UMLS CUI [1,1]
C2983670
UMLS CUI [1,2]
C0422727
UMLS CUI [1,3]
C0011008
Was the subject withdrawn from the study?
Description

Patient withdrawn from trial

Data type

boolean

Alias
UMLS CUI [1]
C0422727
Primary reason for withdrawal
Description

Patient withdrawn from trial, Indication

Data type

text

Alias
UMLS CUI [1,1]
C0422727
UMLS CUI [1,2]
C3146298
Investigational Product - Double Blind
Description

Investigational Product - Double Blind

Alias
UMLS CUI-1
C0304229
UMLS CUI-2
C0013072
Start Date
Description

Experimental drug, Double-Blind Method, Start Date

Data type

date

Alias
UMLS CUI [1,1]
C0013072
UMLS CUI [1,2]
C0808070
UMLS CUI [1,3]
C0808070
Stop Date
Description

Experimental drug, Double-Blind Method, End Date

Data type

date

Alias
UMLS CUI [1,1]
C0013072
UMLS CUI [1,2]
C0808070
UMLS CUI [1,3]
C0806020
Pharmacogenetic (PGx) Research Withdrawal of Consent
Description

Pharmacogenetic (PGx) Research Withdrawal of Consent

Alias
UMLS CUI-1
C0031325
UMLS CUI-2
C1707492
Has subject withdrawn consent for PGx research?
Description

Pharmacogenetics, Consent Withdrawn

Data type

boolean

Alias
UMLS CUI [1,1]
C0031325
UMLS CUI [1,2]
C1707492
Yes, date informed consent withdrawn
Description

Pharmacogenetics, Consent Withdrawn, Date in time

Data type

date

Alias
UMLS CUI [1,1]
C2347500
UMLS CUI [1,2]
C1707492
UMLS CUI [1,3]
C0011008
Has a request been made for sample destruction?
Description

Pharmacogenetics, Blood Specimen, Destruction, Request

Data type

boolean

Alias
UMLS CUI [1,1]
C0031325
UMLS CUI [1,2]
C0178913
UMLS CUI [1,3]
C1948029
UMLS CUI [1,4]
C1272683
Yes, check reason
Description

Pharmacogenetics, Blood Specimen, Destruction, Request, Indication

Data type

text

Alias
UMLS CUI [1,1]
C0031325
UMLS CUI [1,2]
C0178913
UMLS CUI [1,3]
C1948029
UMLS CUI [1,4]
C1272683
UMLS CUI [1,5]
C3146298
Investigator Signature
Description

Investigator Signature

Alias
UMLS CUI-1
C2346576
Is this casebook ready to sign?
Description

Investigator Signature

Data type

boolean

Alias
UMLS CUI [1]
C2346576
Pregnancy Information
Description

Pregnancy Information

Alias
UMLS CUI-1
C0032961
UMLS CUI-2
C1533716
Did the subject become pregnant during the study?
Description

Pregnant during the study

Data type

boolean

Alias
UMLS CUI [1]
C3828490
Back to the top of the page

Similar models

End of Study

1 forms
  1. StudyEvent: ODM
    1. End of Study
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Administrative Data
Study Site
Item
Site
text
C2825164 (UMLS CUI [1])
Clinical trial participant
Item
Subject
text
C1997894 (UMLS CUI [1])
Clinical Trial Subject Unique Identifier
Item
Subject No.
integer
C2348585 (UMLS CUI [1])
Item Group
Status of Treatment Blind
C2347038 (UMLS CUI-1)
C0449438 (UMLS CUI-2)
Subject Unblinding Event Record
Item
Was the treatment blind broken during the study?
boolean
C3897431 (UMLS CUI [1])
Subject Unblinding Event Record, Date in time
Item
Date blind broken
date
C3897431 (UMLS CUI [1,1])
C0011008 (UMLS CUI [1,2])
Item
Reason blind broken
text
C3897431 (UMLS CUI [1,1])
C0392360 (UMLS CUI [1,2])
Subject Unblinding Event Record, Indication
Code List
Reason blind broken
CL Item
Medical emergency requiring identification of investigational product for further treatment (1)
CL Item
Other, specify (2)
Item Group
Follow-Up Contact
C1522577 (UMLS CUI-1)
Follow-up, Contact with, Study subject
Item
Subject contacted for follow-up?
boolean
C1522577 (UMLS CUI [1,1])
C0332158 (UMLS CUI [1,2])
C0681850 (UMLS CUI [1,3])
Item Group
Date of Visit/Assessment
C1320303 (UMLS CUI-1)
C2985720 (UMLS CUI-2)
Date of visit, Assessment Date
Item
Date of visit/assessment
date
C1320303 (UMLS CUI [1,1])
C2985720 (UMLS CUI [1,2])
Item Group
Study Conclusion
C0008976 (UMLS CUI-1)
C1707478 (UMLS CUI-2)
Study End Date, Patient withdrawn from trial, Date in time
Item
Date of subject completion or withdrawal
date
C2983670 (UMLS CUI [1,1])
C0422727 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
Patient withdrawn from trial
Item
Was the subject withdrawn from the study?
boolean
C0422727 (UMLS CUI [1])
Item
Primary reason for withdrawal
text
C0422727 (UMLS CUI [1,1])
C3146298 (UMLS CUI [1,2])
Patient withdrawn from trial, Indication
Code List
Primary reason for withdrawal
CL Item
Adverse Event (1)
CL Item
Lack of efficacy  (2)
CL Item
Exacerbation (3)
CL Item
Protocol Deviation (4)
CL Item
Subject reached protocol defined stopping criteria  (5)
CL Item
Study closed/terminated (6)
CL Item
Lost to Follow-up (7)
CL Item
Withdrew consent (8)
CL Item
Investigator discretion, specify (9)
Item Group
Investigational Product - Double Blind
C0304229 (UMLS CUI-1)
C0013072 (UMLS CUI-2)
Experimental drug, Double-Blind Method, Start Date
Item
Start Date
date
C0013072 (UMLS CUI [1,1])
C0808070 (UMLS CUI [1,2])
C0808070 (UMLS CUI [1,3])
Experimental drug, Double-Blind Method, End Date
Item
Stop Date
date
C0013072 (UMLS CUI [1,1])
C0808070 (UMLS CUI [1,2])
C0806020 (UMLS CUI [1,3])
Item Group
Pharmacogenetic (PGx) Research Withdrawal of Consent
C0031325 (UMLS CUI-1)
C1707492 (UMLS CUI-2)
Pharmacogenetics, Consent Withdrawn
Item
Has subject withdrawn consent for PGx research?
boolean
C0031325 (UMLS CUI [1,1])
C1707492 (UMLS CUI [1,2])
Pharmacogenetics, Consent Withdrawn, Date in time
Item
Yes, date informed consent withdrawn
date
C2347500 (UMLS CUI [1,1])
C1707492 (UMLS CUI [1,2])
C0011008 (UMLS CUI [1,3])
Pharmacogenetics, Blood Specimen, Destruction, Request
Item
Has a request been made for sample destruction?
boolean
C0031325 (UMLS CUI [1,1])
C0178913 (UMLS CUI [1,2])
C1948029 (UMLS CUI [1,3])
C1272683 (UMLS CUI [1,4])
Item
Yes, check reason
text
C0031325 (UMLS CUI [1,1])
C0178913 (UMLS CUI [1,2])
C1948029 (UMLS CUI [1,3])
C1272683 (UMLS CUI [1,4])
C3146298 (UMLS CUI [1,5])
Pharmacogenetics, Blood Specimen, Destruction, Request, Indication
Code List
Yes, check reason
CL Item
Subject withdrew consent for PGx  (1)
CL Item
Screen failure (2)
CL Item
Other, specify (3)
Item Group
Investigator Signature
C2346576 (UMLS CUI-1)
Investigator Signature
Item
Is this casebook ready to sign?
boolean
C2346576 (UMLS CUI [1])
Item Group
Pregnancy Information
C0032961 (UMLS CUI-1)
C1533716 (UMLS CUI-2)
Pregnant during the study
Item
Did the subject become pregnant during the study?
boolean
C3828490 (UMLS CUI [1])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial